RT Journal Article
SR Electronic
T1 Tyrosine kinase inhibitors for metastatic renal cell carcinoma
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 129
OP 132
DO 10.1136/dtb.2011.02.0069
VO 49
IS 11
YR 2011
UL http://dtb.bmj.com/content/49/11/129.abstract
AB Relevant BNF section: BNF 8.1.5 Renal cell carcinoma accounts for 2–3% of all adult malignancies worldwide, and around 30% of patients with the condition present with advanced or metastatic disease.1,2 Until recently, cytokine therapy (e.g. interleukin-2 or interferon-alfa) was the standard treatment for metastatic renal cell carcinoma but provided only a small survival advantage (e.g. extending life by a median of 2.5 months).3 A key development has been the introduction of drugs known as receptor tyrosine kinase inhibitors, which include ▼sunitinib (Sutent – Pfizer), ▼sorafenib (Nexavar – Bayer) and ▼pazopanib (Votrient – GlaxoSmithKline). Here we review the evidence on the efficacy, tolerability and cost-effectiveness of these treatments in renal cell carcinoma.